Related Experiment Video
Updated: Aug 13, 2026
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Published on: May 21, 2010
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias
1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. vcolomer@jhu.edu
Abstract:
Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.
Insights
Machado-Joseph disease (MJD), a neurodegenerative disorder, currently lacks a cure. This review explores potential therapeutic strategies for MJD, focusing on treatments targeting mutant ataxin-3 in mouse models.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3, is a progressive neurodegenerative disorder.
- It is characterized by a polyglutamine expansion in the ataxin-3 gene, leading to toxic protein aggregation.
- Currently, no definitive treatments exist to cure or halt the progression of MJD.
Purpose of the Study:
- To review and compare existing mouse models for MJD and related polyglutamine spinocerebellar ataxias.
- To identify and discuss promising therapeutic strategies for MJD based on preclinical data from these models.
Main Methods:
- Comparative analysis of published research on MJD and polyglutamine spinocerebellar ataxia mouse models.
- Identification of therapeutic targets and approaches discussed in the reviewed literature.
Main Results:
- Mouse models are crucial for understanding MJD pathogenesis and testing interventions.
- Several therapeutic avenues show promise, including targeting mutant ataxin-3 fragments, aggregates, and nuclear localization.
- Reducing mutant ataxin-3 expression in neurons is another key strategy.
Conclusions:
- Therapeutic strategies for MJD focus on mitigating the effects of mutant ataxin-3.
- Interfering with mutant ataxin-3 formation, reducing its nuclear presence, and decreasing its expression are viable treatment approaches.
- Further research using mouse models is essential for developing effective MJD therapies.
